Company intelligence / Profile preview
Unleash Immuno Oncolytics
St. Louis, Missouri, United Statesunleash.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Unleash Immuno Oncolytics develops genetically engineered oncolytic adenoviruses designed to target both malignant cancer cells and the supportive stromal environment that enables metastasis. Their lead candidate, UIO‑512, aims at refractory solid tumors by infecting both tumor and stroma cells. Another program, UIO‑702, incorporates a camelid antibody into the viral fiber to evade human immune responses for systemic delivery against metastatic cancers. The company has attracted investment from strategic partners such as Oncolys BioPharma but has not yet reported clinical trial results or late-stage data.
- Therapeutic areas
- Oncology
- Modalities
- Genetically engineered oncolytic adenovirusesCancer immunotherapy virusesViruses with incorporated camelid antibodies (for immune evasion)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Oncolys BioPharma Inc.—strategic investor and collaborator; holds board seat at Unleash Immuno Oncolytics.Precision Virologics—Unleash held shares in this Washington University biotech venture related to gene-modification technology.
Beyond the preview
Go deeper on Unleash Immuno Oncolytics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Unleash Immuno Oncolytics.